Navigation Links
Haemacure Adopts Strategy for "First-Patient-In" Fibrin Sealant Pivotal Clinical Trials


MONTREAL, Oct. 24 /PRNewswire-FirstCall/ - Haemacure Corporation (TSX : HAE), a Montreal-based specialty bio-therapeutics company, is pleased to announce a new two-phase strategy to have a first patient undergo surgery in the pivotal clinical trials for its lead product candidate, the Hemaseel(R)HMN fibrin sealant, during the first quarter of 2009.


This "First-Patient-In" objective is a major milestone in bringing Haemacure's lead product candidate to market. Haemacure's new two-phase strategy will greatly facilitate meeting this objective. The new strategy consists of setting-up a small-scale manufacturing facility by mid-2008, where product will be manufactured for clinical trials and commercial launch, and afterwards setting-up the large-scale facility originally planned. Both facilities will be set-up in premises currently leased by Haemacure in Florida.

Setting-up the small-scale facility requires significantly lower capital expenditures than the original plan. Haemacure will finance the first phase of its new strategy in part with existing liquidities and seek financing for manufacturing equipment.

The pivotal trials will be carried out under the existing IND currently open with the US FDA. The timeline for the commercial launch of the fibrin sealant remains the same as previously announced, towards the end of 2010.

"The benefit of this two-phase strategy is that Haemacure will not require additional equity to have a first patient in the clinic and set-up the small-scale facility", said Joseph Galli, Chairman and CEO of Haemacure.

Shipping Fibrin Sealant for Evaluation

Haemacure recently equipped and staffed a laboratory in Montreal where it has commenced producing small volumes of its fibrin sealant to respond to requests from potential partners for evaluation in various applications. Haemacure plans on commencing delivery of its sample fibrin sealant to these potential partners before the end of 2007. In addition to the bio-surgical applications of its fibrin sealant, Haemacure is positioning itself to become an exclusive, long-term supplier of fibrin sealant to the drug delivery and regenerative medicine markets.

Therapeutic Proteins and Enzymes

Haemacure is also continuing work on the content analysis of its plasma fractions and is engaged with potential partners in examining how to develop and bring these proteins and enzymes to market.

"I am extremely excited about Haemacure's prospects within our industry as well as our positioning as an up-and-coming independent player in markets expected to grow at double-digit rates over the foreseeable future. We believe that the benefits of our protein extraction technology, delivering high quality products and high production yields, will translate into significantly higher gross margins than industry average" Mr. Galli concluded.

About Haemacure

Haemacure Corporation is a specialty biotherapeutics company developing high-value human therapeutic proteins for commercialization. Haemacure's research and development effort is driven by its proprietary plasma protein extraction technology to develop next-generation products, including surgical hemostats. Haemacure's lead product candidate, Hemaseel(R)HMN, is a human-derived fibrin sealant in late-stage clinical development. Haemacure's second product candidate is human thrombin, a component of its fibrin sealant. Both candidates have applications in the expanding biosurgical market. Follow-on development will focus on surgical hemostats, biomaterial combinations and drug delivery in select therapeutic areas. Haemacure has discovered additional specialty proteins in its plasma-derived fraction and will advance these specialty proteins through partnerships with pharmaceutical and biotechnology companies. Haemacure also operates offices in Sarasota, Florida through a wholly-owned subsidiary. The Corporation is traded under stock symbol HAE on the TSX.

Forward-looking Statements

Certain of the statements contained in this news release are forward-looking statements. Such statements, based as they are on the current expectations of management, inherently involve numerous risks and uncertainties, known and unknown. Some examples of known risks are: the impact of general economic conditions, general conditions in the biotech industry, changes in the regulatory environment in the jurisdictions in which Haemacure does business, stock market volatility, fluctuations in costs, and changes to the competitive environment due to consolidation or otherwise. Consequently, actual future results may differ materially from the anticipated results expressed in the forward-looking statements. Haemacure disclaims any intention or obligation to update these statements.

Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Gates Foundation Adopts Fight against Encephalitis
2. Haryana Adopts New Rules for Private Schools
3. Ujjain Ashram Adopts Eco-friendly Burial Process
4. AEternas acquisition of Zentaris being followed up with its new product pipeline and clinical development strategy
5. Novel Strategy To Combat Alzheimer’s Disease
6. "Defensive Pessimism" Before Exam Results Not a Good Strategy
7. West Nile Virus Can Be Tackled By New Strategy
8. WHO Devises New Global Strategy To Fight Tuberculosis
9. HER-2 Positive Breast Cancer Patients May Benefit With a Combo Drug Strategy
10. Australia Set To Implement A national Strategy Tackle Cannabis Abuse
11. Bird flu no threat to McDonalds chicken: Advertisement strategy
Post Your Comments:
(Date:12/1/2015)... ... ... is the first health care provider in the region to offer the vBloc® Therapy ... vagal blocking therapy, delivered via the Maestro® System, for the treatment of adult patients over ... to 45 kg, or a BMI of at least 35 to 39.9 kg with a ...
(Date:12/1/2015)... ... December 01, 2015 , ... Dr. Paul Vitenas, one of the ... been named by MedEsthetics magazine as the Best Single Physician Practice in the nation. ... many elite aesthetic physicians honored by the industry publication. , Dr. Vitenas said ...
(Date:12/1/2015)... Delaware (PRWEB) , ... December 01, 2015 , ... ... winner at the 7th Annual 2015 Golden Bridge Business Awards under the New ... is a zero capex web based sample management software that helps ...
(Date:12/1/2015)... ... 2015 , ... For many X-rays taken at hospitals, doctors’ ... by the radiologist. The marking utensils are so small, however, they are difficult ... way to alleviate this problem. , He developed the patent-pending MARK N SHOW ...
(Date:12/1/2015)... ... December 01, 2015 , ... ... it has been awarded a fixed price per sprint agile development contract to ... at $34 million over five years, provides software engineering, infrastructure, as well as ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... Pa. , Dec. 1, 2015  Today, ... announced the launch of CareFront, a first-of-its-kind population ... patients diagnosed with cancer. Designed to be built ... diagnosed cancer patients with resources for their care ... The program also offers tools to help patients ...
(Date:12/1/2015)... , Dec. 1, 2015   Craneware, ... value cycle solutions, today announced the company will ... Pharmacy ChargeLink ® solution at the ... Midyear Clinical Meeting . The new features are ... process of monitoring and managing enterprise-wide pharmacy charges ...
(Date:12/1/2015)... 1, 2015  Booth #3506 – Claymount is featuring its ... meeting of the Radiological Society of North America ... year. Based in the Netherlands , Claymount ... Systems (NYSE: VAR ) and is one of the ... solid state automatic exposure control systems for controlling dose during ...
Breaking Medicine Technology: